Pfizer Forecasts $54 Billion in Sales This Year as Demand for COVID-19 Vaccine and Treatment Pill Continues

The Pfizer Inc. logo is seen outside the company's headquarters in New York City on March 2, 2021. Carlo Allegri/Reuters

Pfizer on Tuesday said it expects to see continued demand for its products this year, forecasting $54 billion in combined sales of its COVID-19 vaccine shots and antiviral pills.

The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in 2022 as demand for the products continues.